23,473 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Calamos Advisors LLC

Calamos Advisors LLC acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 23,473 shares of the company’s stock, valued at approximately $2,474,000.

Several other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Protagonist Therapeutics by 27.2% in the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock valued at $472,832,000 after buying an additional 1,156,461 shares in the last quarter. State Street Corp increased its stake in Protagonist Therapeutics by 18.5% in the second quarter. State Street Corp now owns 3,207,543 shares of the company’s stock valued at $177,281,000 after acquiring an additional 500,924 shares during the last quarter. Wellington Management Group LLP raised its position in Protagonist Therapeutics by 66.2% during the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock valued at $276,992,000 after purchasing an additional 1,262,977 shares in the last quarter. UBS Group AG raised its position in Protagonist Therapeutics by 46.1% during the fourth quarter. UBS Group AG now owns 2,770,021 shares of the company’s stock valued at $241,934,000 after purchasing an additional 874,013 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in Protagonist Therapeutics by 140.7% during the fourth quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock valued at $231,355,000 after purchasing an additional 1,549,160 shares in the last quarter. 98.63% of the stock is owned by institutional investors.

Insider Transactions at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the sale, the chief executive officer owned 523,478 shares of the company’s stock, valued at $52,410,617.36. This trade represents a 12.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Bryan Giraudo sold 36,000 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $100.14, for a total value of $3,605,040.00. Following the sale, the director owned 27,825 shares in the company, valued at $2,786,395.50. This represents a 56.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 162,880 shares of company stock valued at $16,539,792 over the last quarter. 5.19% of the stock is currently owned by insiders.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX opened at $135.46 on Thursday. Protagonist Therapeutics, Inc. has a one year low of $50.49 and a one year high of $141.10. The company has a market cap of $8.71 billion, a price-to-earnings ratio of -74.84 and a beta of 1.79. The firm has a 50 day simple moving average of $112.01 and a 200 day simple moving average of $99.04.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. The firm had revenue of $56.37 million for the quarter, compared to analysts’ expectations of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. As a group, analysts expect that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Citigroup reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Wall Street Zen cut Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Leerink Partners boosted their price target on Protagonist Therapeutics from $107.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. JPMorgan Chase & Co. upped their price objective on Protagonist Therapeutics from $95.00 to $106.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. Finally, Wolfe Research began coverage on Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $119.21.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.